Brief · Use case · Corporate Development
Gene Therapy Developer Scan.
LiveScanTake stock of the companies developing gene therapies for a named rare disease, grouped by approach and stage, with the boundary and method stated.
Gene Therapy Developer Scan is a ready-made use case for Corporate Development. It ships under the Scan template.
For corporate development leads building a long list. You get the inclusion rule and method first, each company with its category and maturity, how the field divides and what was not looked at. Entries are cited or marked as gaps, and nothing is ranked.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
Which companies have a gene therapy in clinical development for a named rare monogenic disease, for a business development lead building a partner list?
What is scanned
A developer is listed when a public record shows a gene therapy in clinical development for the named disease. The scan names the disease first and says how it matched records to companies.
| Source | What it holds | What the scan does with it |
|---|---|---|
| Trial registers | Registered clinical studies of gene therapies for the named disease, with the sponsor.2,3 | Lists each sponsor once, with its program and the register entry. |
| FDA approved cellular and gene therapy products | The cellular and gene therapy products FDA has licensed, listed with trade name and manufacturer. FDA’s page, current as of 17 September 2026, lists about 54 products.1 | Marks any developer whose product is already licensed for the named disease and separates it from developers still in development. |
| Company disclosures | Pipeline statements and filings in which a company describes its programs. | Lists them as signals with a lower maturity than a registered trial. |
What the scan does
Already licensed, or still in development. FDA’s list of licensed products is the check that separates a program already on the market from one in development. The scan uses it to avoid listing a licensed product as an emerging program.1
One row per company. A company with several programs appears once, with its programs listed together, so the partner list is a list of companies and not of studies.
Maturity, as analyst judgment. A program with a registered recruiting trial is rated differently from a program known only from a corporate statement. The labels are Established, Emerging or Weak signal, and they are judgment.
What a partner list cannot tell you. The scan lists who is developing. It does not say who would partner, on what terms, or with what rights.
Recommended length
Standard
One rare disease gives a short list of developers. Standard carries the boundary, the list, how the field divides and what was not covered in about 1,300 words.
You can pick another length on the form. The other two stay available.
Assumptions the scan checks
The scan states the assumptions its boundary and its sources rest on, and the closing section says what they leave out. Examples for this subject:
- The named disease is defined by a single standard name the scan states, so synonyms are searched.
- A registered trial reflects the company’s current program.
- The FDA list is current on the scan date and covers the products the question is about.
Standards, guidance and sources
Primary records
The decision practice behind the memo itself is on the template page.
What gets flagged
Any developer known only from its own statement, any program for a different form of the disease, and any licensed product that the scan separates from the in-development list.
What arrives
- Scope and boundary
- How the scan was run
- What is out there
- How the field divides
- What stands out
- What this does not cover
What it will not do
It does not rank or score the items it finds, and it does not recommend one. A scan lists what exists; when you need a view on it, run a Comparison or a Decision Memo on the items you choose.
It does not assess a company’s science or finances, and it does not say who would make a good partner.
It does not rank or score the items. A scan says what exists; it does not say which item is preferable.
It is a snapshot of one date. It does not monitor the field after that date.
It lists what it could find in the sources it names. Items in sources it could not open are listed as not covered.
References
- [1] U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Content current as of 17 September 2026. Read on 9 October 2026.
- [2] U.S. National Library of Medicine. ClinicalTrials.gov. Search on a stated date; results change.
- [3] European Medicines Agency. Clinical Trials Information System (CTIS) public site. Search on a stated date; results change.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Brief service
A Brief is a written answer from one specialist, at the depth you asked for. It arrives with its sources, and it closes by saying plainly what would change the conclusion. Nothing is hidden behind a summary, and anything the expert could not source is marked as a gap rather than filled in.
To edit a saved template, open New → Brief → From template, or the library rail on the service form.